The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo
BeiGene is looking increasingly like it will become the leading challenger to AbbVie and Johnson & Johnson's market-leading BTK inhibitor Imbruvica for cancer, after besting its rival i
BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM
Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but is already planning a move the drug into the first-line se
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.
UK startup Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases that comes with $85 million upfront payment and
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho
